$11.76
1.47% yesterday
NYSE, Aug 21, 10:00 pm CET
ISIN
US37611X1000
Symbol
DNA
Sector
Industry

Ginkgo Bioworks Stock price

$11.76
+0.44 3.89% 1M
+0.94 8.69% 6M
+1.94 19.76% YTD
+2.45 26.32% 1Y
-95.84 89.07% 3Y
-393.04 97.09% 5Y
-393.04 97.09% 10Y
-393.04 97.09% 20Y
NYSE, Closing price Thu, Aug 21 2025
+0.17 1.47%
ISIN
US37611X1000
Symbol
DNA
Sector
Industry

Key metrics

Basic
Market capitalization
$696.2m
Enterprise Value
$222.5m
Net debt
positive
Cash
$473.7m
Shares outstanding
55.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.0 | 3.9
EV/Sales
1.0 | 1.2
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
52.0%
Return on Equity
-76.4%
ROCE
-26.8%
ROIC
-42.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$230.8m | $180.0m
EBITDA
$-240.3m | $-180.8m
EBIT
$-304.3m | $-343.9m
Net Income
$-315.2m | $-343.0m
Free Cash Flow
$-274.2m
Growth (TTM | estimate)
Revenue
25.2% | -20.7%
EBITDA
48.7% | 57.0%
EBIT
42.8% | 28.8%
Net Income
64.9% | 37.3%
Free Cash Flow
20.9%
Margin (TTM | estimate)
Gross
79.0%
EBITDA
-104.1% | -100.5%
EBIT
-131.8%
Net
-136.6% | -190.6%
Free Cash Flow
-118.8%
More
EPS
$-5.7
FCF per Share
$-4.9
Short interest
18.0%
Employees
834
Rev per Employee
$270.0k
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
9%
2x Hold
18%
8x Sell
73%

Analyst Opinions

11 Analysts have issued a Ginkgo Bioworks forecast:

Buy
9%
Hold
18%
Sell
73%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
231 231
25% 25%
100%
- Direct Costs 48 48
33% 33%
21%
182 182
23% 23%
79%
- Selling and Administrative Expenses 209 209
54% 54%
91%
- Research and Development Expense 278 278
49% 49%
120%
-240 -240
49% 49%
-104%
- Depreciation and Amortization 64 64
0% 0%
28%
EBIT (Operating Income) EBIT -304 -304
43% 43%
-132%
Net Profit -315 -315
65% 65%
-137%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Neutral
PRNewsWire
2 days ago
BOSTON , Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to delive...
Neutral
PRNewsWire
10 days ago
Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON , Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointmen...
Positive
Seeking Alpha
11 days ago
Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates have plunged, raising concerns about future growth. Despite cost reductions, Ginkgo continues to post large operating losses and faces ongoing cash burn, prompting a $500 million shelf offering.
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 834
Founded 2008
Website investors.ginkgobioworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today